aTYR PHARMA INC Increase Decrease In Operating Lease Liability
aTYR PHARMA INC (ATYR) reported Increase Decrease In Operating Lease Liability of -$399.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-07
- aTYR PHARMA INC increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$208.00K.
- aTYR PHARMA INC increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$191.00K.
- aTYR PHARMA INC increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$187.00K, a 181.30% decline year-over-year.
- aTYR PHARMA INC increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$183.00K.
- aTYR PHARMA INC increase decrease in operating lease liability for fiscal 2025 was -$711.00K.
- aTYR PHARMA INC increase decrease in operating lease liability for fiscal 2024 was -$343.00K, a 116.54% decline from fiscal 2023.
- aTYR PHARMA INC increase decrease in operating lease liability for fiscal 2023 was $2.07M, a 1.75% decline from fiscal 2022.
- aTYR PHARMA INC increase decrease in operating lease liability for fiscal 2022 was $2.11M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$208.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$399.00K 10-Q · filed 2026-08-07 | -$586.00K derived: sum of 3 quarters · filed 2026-08-07 | -$769.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$191.00K 10-Q · filed 2026-05-15 | -$378.00K derived: sum of 2 quarters · filed 2026-05-15 | -$561.00K derived: sum of 3 quarters · filed 2026-05-15 | -$740.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$370.00K derived: sum of 2 quarters · filed 2026-03-05 | -$549.00K derived: sum of 3 quarters · filed 2026-08-07 | -$711.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | -$183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$362.00K derived: sum of 2 quarters · filed 2026-08-07 | -$524.00K 10-Q · filed 2025-11-06 | -$294.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$179.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$341.00K 10-Q · filed 2026-08-07 | -$111.00K derived: sum of 3 quarters · filed 2026-08-07 | -$267.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$162.00K 10-Q · filed 2026-05-15 | $68.00K derived: sum of 2 quarters · filed 2026-05-15 | -$88.00K derived: sum of 3 quarters · filed 2026-05-15 | -$240.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $74.00K derived: sum of 2 quarters · filed 2026-03-05 | -$78.00K derived: sum of 3 quarters · filed 2026-03-05 | -$343.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$156.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$308.00K derived: sum of 2 quarters · filed 2025-11-06 | -$573.00K 10-Q · filed 2025-11-06 | -$616.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | -$152.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$417.00K 10-Q · filed 2025-08-07 | -$460.00K derived: sum of 3 quarters · filed 2026-03-05 | -$690.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | -$265.00K 10-Q · filed 2025-05-07 | -$308.00K derived: sum of 2 quarters · filed 2026-03-05 | -$538.00K derived: sum of 3 quarters · filed 2026-03-05 | -$210.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | -$43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$273.00K derived: sum of 2 quarters · filed 2026-03-05 | $55.00K derived: sum of 3 quarters · filed 2026-03-05 | $2.07M 10-K · filed 2026-03-05 |
| 2023-09-30 | -$230.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $98.00K derived: sum of 2 quarters · filed 2024-11-07 | $2.12M 10-Q · filed 2024-11-07 | $4.72M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $328.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.35M 10-Q · filed 2024-08-13 | $4.95M derived: sum of 3 quarters · filed 2025-03-13 | $4.93M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $2.02M 10-Q · filed 2024-05-02 | $4.62M derived: sum of 2 quarters · filed 2025-03-13 | $4.60M derived: sum of 3 quarters · filed 2025-03-13 | $4.36M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.58M derived: sum of 2 quarters · filed 2025-03-13 | $2.34M derived: sum of 3 quarters · filed 2025-03-13 | $2.11M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$255.00K derived: sum of 2 quarters · filed 2023-11-09 | -$488.00K 10-Q · filed 2023-11-09 | -$716.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$239.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$472.00K 10-Q · filed 2023-08-09 | -$700.00K derived: sum of 3 quarters · filed 2024-03-14 | -$919.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | -$233.00K 10-Q · filed 2023-05-09 | -$461.00K derived: sum of 2 quarters · filed 2024-03-14 | -$680.00K derived: sum of 3 quarters · filed 2024-03-14 | -$890.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | -$228.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$447.00K derived: sum of 2 quarters · filed 2024-03-14 | -$657.00K derived: sum of 3 quarters · filed 2024-03-14 | -$861.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | -$219.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$429.00K derived: sum of 2 quarters · filed 2022-11-14 | -$633.00K 10-Q · filed 2022-11-14 | -$833.00K derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-06-30 | -$210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$414.00K 10-Q · filed 2022-08-15 | -$614.00K derived: sum of 3 quarters · filed 2023-03-14 | |
| 2021-03-31 | -$204.00K 10-Q · filed 2022-05-10 | -$404.00K derived: sum of 2 quarters · filed 2023-03-14 | ||
| 2020-12-31 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$755.00K 10-K · filed 2023-03-14 | ||
| 2020-09-30 | -$555.00K 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | -$498.00K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |